DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Applications Concerning Specific Inhibitors and Therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins

AGENCY: Department of the Army, DoD.

ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of the related U.S. patent applications concerning “Specific Inhibitors and therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins” listed below. The United States Government, as represented by the Secretary of the Army, has rights in these inventions. Foreign rights are also available. The following patents are available for licensing:

(1) U.S. Patent Application No.: 09/570,022. Filed: May 12, 2000. Title: Previsins as Specific Inhibitors and Therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins. Supplementary Information: The compounds of the invention may be used as molecular building blocks to create compounds that are optimized for inhibiting the protease activity of Botulinum B and tetanus toxins. Foreign rights (PCT/US00/13215) are also available.


ADDRESS: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702–5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619–6664, both at telefax (301) 619–5034.